Elsevier

Cytokine

Volume 52, Issue 3, December 2010, Pages 215-220
Cytokine

Macrophage-colony stimulating factor and interleukin-34 induce chemokines in human whole blood

https://doi.org/10.1016/j.cyto.2010.08.005Get rights and content

Abstract

The aim of this study is to investigate if macrophage-colony stimulating factor (M-CSF) or interleukin-34 (IL-34) induces cytokines or chemokines using human whole blood (HWB) and if an M-CSF- or IL-34-induced cytokine or chemokine production from HWB is inhibited by soluble M-CSF receptor or c-FMS kinase inhibitors. Among eight cytokines or growth factors tested, only IL-6 level was increased by up to 6-fold by M-CSF or IL-34 in HWB. In contrast, chemokine levels (IP-10/CXCL10, IL-8/CXCL8, and MCP-1/CCL2) were dramatically increased by M-CSF or IL-34 in HWB while exhibiting a large variation among donors. Variability of the MCP-1 signal induced by M-CSF or IL-34 was relatively less among donors compared to the IP-10 and IL-8 signals. The elevation of these chemokine levels was significantly decreased by soluble M-CSF receptor, indicating the elevation of these chemokines was mediated by M-CSF or IL-34. Furthermore, GW2580, a c-FMS kinase inhibitor, inhibited the induction of MCP-1 by M-CSF or IL-34 in a concentration dependent manner. These indicate MCP-1 is the most appropriate chemokine target for a chemokine release assay to evaluate the potency of c-FMS kinase inhibitors and MCP-1 release assay using HWB would be useful, relevant tool for translational pharmacology of c-FMS kinase inhibitors.

Introduction

Macrophage-colony stimulating factor (M-CSF) promotes the survival, proliferation, and differentiation of mononuclear phagocyte lineages, which include monocytes, macrophages and osteoclasts [1], [2], [3]. M-CSF is synthesized by a variety of cell types, such as endothelial cells, osteoblasts, and fibroblast and binds to a single receptor, CSF-1R (c-FMS) that is encoded by the c-fms proto-oncogene and also exclusively expressed on mononuclear phagocyte, resulting in autophosphorylation by c-FMS kinase and a subsequent cascade of intracellular signals including phosphoinositol-3 (PI-3) kinase, mitogen-activated protein kinase (MAPK), and JAK/Stat pathways [4], [5]. Recently, a novel cytokine, interleukin-34 (IL-34) has been found to bind to the CSF-1R and promote monocyte viability with characteristics similar to M-CSF [6].

M-CSF plays important roles in innate immunity, cancer and inflammatory diseases, including systemic lupus erythematosus, atherosclerosis, obesity and rheumatoid arthritis (RA) [2]. M-CSF-c-FMS-pathway has reported to have a certain role in pathogenesis in RA. M-CSF is not only elevated in the synovial fluid of the patients with RA but is constitutively produced by synovial fibroblasts from RA patients [7], [8], [9]. Plasma levels of M-CSF were significantly higher in RA patients with increased number of CD16+ monocyte than in healthy controls [9]. Furthermore, M-CSF, in collaboration with nuclear factor kappa B ligand (RANKL), contributes to the differentiation of macrophages into osteoclasts, which are involved in bone destruction in RA [10]. In animal model, M-CSF-deficient mice were resistant to collagen-induced arthritis [11]. Furthermore, administration of an anti-M-CSF antibody reduced severity whereas administration of exogenous M-CSF exacerbated symptoms in mousse arthritis model [11], [12]. These indicate that M-CSF-c-FMS signaling pathway is a potential therapeutic target in RA ([2] and references therein). These extensive researches have led to the development of small molecule c-FMS kinase inhibitors showing efficacy in arthritis models in animals [13], [14], [15]. In these reports, cell proliferation assay using myeloid cell lines or primary bone marrow-derived macrophages was applied to evaluate potency of compounds as M-CSF is the predominant growth factor or survival factor for macrophage lineage cells. Also, differentiation of macrophages derived from mice with M-CSF enhances LPS-induced cytokine or chemokine production [16], [17], [18], [19]. Furthermore, M-CSF differentiated macrophage derived from human produced cytokines or chemokines in the presence or absence of LPS and also M-CSF-mediated chemokine production from macrophages was antagonized by c-FMS kinase inhibitors [19], [20], [21]. Thus, M-CSF-dependent priming for production of proinflammatory mediators has been well characterized. However, induction of proinflammatory cytokines and chemokines by M-CSF in ex vivo assay, i.e. assay using whole blood has not fully investigated to understand a role of M-CSF in the induction of proinflammatory mediators in whole blood. Furthermore, cell functional assays using downstream signals of phosphorylation of c-FMS have not yet been fully established except for cell proliferation assay using monocytic cell line to investigate translational pharmacology of c-FMS kinase inhibitors.

In current study, we investigated if M-CSF or IL-34 induces cytokines or chemokines using human whole blood (HWB) and if an M-CSF- or IL-34-induced cytokine or chemokine production from HWB is inhibited by c-FMS kinase inhibitors. Also, we investigate whether IL-34 has the function similar to M-CSF in the induction of proinflammatory mediators in HWB.

Section snippets

Human whole blood (HWB)

HWB was obtained from venous blood of donors collected anonymously with informed consent at an on-site clinic into sodium heparin tubes and used immediately.

Measurement of cytokine and chemokine level in HWB

HWB was incubated with or without GW2580, a specific c-FMS kinase inhibitor [15] for 45 min at 37 °C and then M-CSF or IL-34 (100 ng/ml) was added into the plate and the plate was further incubated for 2, 6, and 20 h at 37 °C. In the assay using recombinant human M-CSF receptor/Fc chimera, M-CSF or IL-34 was incubated with recombinant human

Cytokine or chemokine induction by M-CSF or IL-34 in HWB

Firstly, induction of cytokines or chemokines by M-CSF or IL-34 was investigated using HWB (Table 1). Among eight cytokines or growth factors tested, IL-1β, IL-6, TNFα, and GM-CSF levels in HWB were significantly elevated by M-CSF and IL-34 while the level of the elevation was small except for IL-6. Other cytokines were not elevated by M-CSF or IL-34 in HWB. Chemokine levels in HWB induced by M-CSF or IL-34 are shown in Table 2. Among seven chemokines tested, levels of IP-10/CXCL10, IL-8/CXCL8,

Discussion

In this study, we have demonstrated that proinflammatory cytokines and chemokines were induced by M-CSF and IL-34 in HWB. IL-34 is newly identified cytokine that binds to the CSF-1R and promotes monocyte viability with characteristics similar to M-CSF [6]. Also, IL-34 promotes osteoclast development in combination with RANK ligand which function is the same as that of M-CSF [22]. We elucidated that IL-34 promotes osteoclast development through M-CSF receptor (Zack M, in preparation). In this

Acknowledgements

We thank Molly K. Hall and Becky L. Hood for experimental support during HWB assay.

References (46)

  • J.A. Hamilton

    Colony-stimulating factors in inflammation and autoimmunity

    Nat Rev Immunol

    (2008)
  • H. Lin et al.

    Discovery of a cytokine and its receptor by functional screening of the extracellular proteome

    Science

    (2008)
  • H. Kawaji et al.

    Macrophage colony-stimulating factor in patients with rheumatoid arthritis

    Nippon Ika Daigaku Zasshi

    (1995)
  • M. Seitz et al.

    Constitutive mRNA and protein production of macrophage colony-stimulating factor but not of other cytokines by synovial fibroblasts from rheumatoid arthritis and osteoarthritis patients

    Br J Rheumatol

    (1994)
  • N. Kawanaka et al.

    CD14+, CD16+ blood monocytes and joint inflammation in rheumatoid arthritis

    Arthritis Rheum

    (2002)
  • L. Danks et al.

    Synovial macrophage-osteoclast differentiation in inflammatory arthritis

    Ann Rheum Dis

    (2002)
  • I.K. Campbell et al.

    The colony-stimulating factors and collagen-induced arthritis: exacerbation of disease by M-CSF and G-CSF and requirement for endogenous M-CSF

    J Leukoc Biol

    (2000)
  • R.J. Bischof et al.

    Exacerbation of acute inflammatory arthritis by the colony-stimulating factors CSF-1 and granulocyte macrophage (GM)-CSF: evidence of macrophage infiltration and local proliferation

    Clin Exp Immunol

    (2000)
  • H. Ohno et al.

    The orally-active and selective c-Fms tyrosine kinase inhibitor Ki20227 inhibits disease progression in a collagen-induced arthritis mouse model

    Eur J Immunol

    (2008)
  • J.G. Conway et al.

    Effects of thec-FMS kinase inhibitor 5-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine (GW2580) in normal and arthritic rats

    J Pharmacol Exp Ther

    (2008)
  • R. Evans et al.

    Synergistic interaction of bacterial lipopolysaccharide and the monocyte–macrophage colony-stimulating factor: potential quantitative and qualitative changes in macrophage produced cytokine bioactivity

    J Leukoc Biol

    (1992)
  • A.J. Fleetwood et al.

    Granulocyte–macrophage colony-stimulating factor (CSF) and macrophage CSF-dependent macrophage phenotypes display differences in cytokine profiles and transcription factor activities: implications for CSF blockade in inflammation

    J Immunol

    (2007)
  • M.J. Sweet et al.

    Colony-stimulating factor-1 suppresses responses to CpG DNA and expression of toll-like receptor 9 but enhances responses to lipopolysaccharide in murine macrophages

    J Immunol

    (2002)
  • Cited by (66)

    • Role of macrophages in tumor development

      2022, Recent Advancements in Microbial Diversity: Macrophages and their Role in Inflammation
    • Biological functions and clinical implications of interleukin-34 in inflammatory diseases

      2020, Advances in Protein Chemistry and Structural Biology
      Citation Excerpt :

      Taken together, IL-34 can bind to several different receptors, each of which activates different signaling cascades with distinct cellular functions. IL-34 is known to modulate the inflammatory response and is involved in the pathogenesis of inflammatory diseases (Guillonneau, Bézie, & Anegon, 2017; Boulakirba et al., 2018; Eda et al., 2010). IL-34 levels were found to be elevated in experimental colitis and in patients with inflammatory bowel disease (Zwicker et al., 2015).

    • Interleukin-34 as a promising clinical biomarker and therapeutic target for inflammatory arthritis

      2019, Cytokine and Growth Factor Reviews
      Citation Excerpt :

      More recently, IL-34 was found to trigger IL-6 expression in monocyte-like cell line (THP-1) co-cultured with RA CD4+ cells, and this effect was impeded by CSF-1R antagonist [56]. This previous finding supports Eda’s investigation, which noted a significant decline in the ability of IL-34 to influence the production of chemokines by a CSF-1R kinase inhibitor like GW2580 [52], indicating the possible influence of IL-34 interacting with CSF-1R in modulating the release of autoimmune-related components responsible for inflammation in RA. Besides synovial inflammation-mediated immune deregulation, osteoclastogenesis induced by pro-inflammatory cytokines is well-established as an important mechanism implicated in the pathogenesis of RA [59].

    View all citing articles on Scopus
    View full text